ACAD vs XENE: stock comparison and AI forecast
Acadia Pharmaceuticals Inc (ACAD) and Xenon Pharmaceuticals Inc. (XENE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ACAD Acadia Pharmaceuticals Inc
- Market Cap
- $3.66B
- P/E Ratio
- 9.7x
- Size
- mid-cap
- AI Forecast
XENE Xenon Pharmaceuticals Inc.
- Market Cap
- $3.65B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ACAD and XENE have similar market capitalizations ($3.66B and $3.65B).
- ACAD carries 0.29 times debt per unit of equity, against 0.04 times for XENE.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ACAD | XENE |
|---|---|---|
| Market Cap | $3.66B | $3.65B |
| P/E Ratio | 9.70x | – |
| P/B Ratio | 2.64x | 2.94x |
| EPS | $2.19 | $-5.57 |
| Book Value/Share | $8.05 | $12.83 |
| Revenue/Share | $6.98 | $0.00 |
| FCF/Share | $0.48 | $-3.50 |
Profitability & Margins
| Metric | ACAD | XENE |
|---|---|---|
| ROE | 26.1% | -32.9% |
| ROA | 20.2% | -31.6% |
| ROIC | 8.4% | -35.3% |
| Gross Margin | 90.5% | – |
| Operating Margin | 10.2% | – |
| Net Margin | 30.1% | – |
| EBT Margin | 13.1% | – |
| Tax Rate | -130.4% | 0.5% |
Financial Health
| Metric | ACAD | XENE |
|---|---|---|
| Current Ratio | 3.82x | 21.02x |
| Quick Ratio | 3.50x | – |
| D/E Ratio | 0.29x | 0.04x |
| Financial Leverage | 1.29x | 1.04x |
| Interest Coverage | – | -4.2x |
| Working Capital | $936M | $901M |
Cash Flow
| Metric | ACAD | XENE |
|---|---|---|
| Operating Cash Flow | $98M | -$338M |
| Free Cash Flow | $82M | -$339M |
| Capital Spending | -$16M | -$1M |
| OCF Growth YoY | -51.0% | – |
| FCF/Sales | 6.8% | – |
| CapEx/Sales | 1.3% | – |
Operational Efficiency
| Metric | ACAD | XENE |
|---|---|---|
| Asset Turnover | 0.67x | 0.00x |
| Receivables Turnover | 7.5x | – |
| Inventory Turnover | 1.1x | – |
| Fixed Assets Turnover | 65.3x | 0.0x |
| Days Sales Outstanding | 49 days | – |
| Days Inventory | 341 days | – |
| Payables Period | 52 days | – |
| Cash Conversion Cycle | 338 days | – |
Income Statement
| Metric | ACAD | XENE |
|---|---|---|
| Total Revenue | $1.20B | $0.00M |
| Operating Income | $122M | -$442M |
| Net Income | $362M | -$409M |
| R&D Expense | $319M | $352M |
| SG&A Expense | $646M | – |
| Cost of Goods Sold | $114M | – |
Dividend & Shareholder Information
| Metric | ACAD | XENE |
|---|---|---|
| Shares Outstanding | 172M | 97M |
| Net Income Growth | 38.7% | – |
| EPS Growth | 38.6% | – |
ACAD vs XENE: stock comparison and AI forecast
Which is bigger, ACAD or XENE?
ACAD and XENE have similar market capitalizations ($3.66B and $3.65B).
Which one does Intratio's AI model rank higher, ACAD or XENE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.